What Happened

On March 13, 2026, the FDA expanded the approval of GSK's Arexvy vaccine to include adults aged 18 to 49 years who are at high risk for severe respiratory syncytial virus (RSV) disease. This new indication allows healthcare providers to offer Arexvy to a younger demographic that may be particularly vulnerable to lower respiratory tract infections (LRTI) caused by RSV. Previously, the vaccine was only approved for older adults and those with specific risk factors.

Why It Matters

RSV is a leading cause of respiratory illness, particularly among vulnerable populations, including infants, older adults, and individuals with chronic health conditions. In recent years, the burden of RSV in adults has become increasingly recognized, with significant hospitalization rates reported among younger adults with underlying health issues. The expansion of Arexvy's approval to include high-risk adults aged 18 to 49 years represents a crucial step in addressing this gap in prevention. This demographic often includes individuals with chronic respiratory or cardiovascular conditions, making them particularly susceptible to severe RSV outcomes. By providing a preventive option, healthcare providers can potentially reduce the incidence of severe RSV-related complications in this younger population.

What Changed

  • Arexvy is now approved for adults aged 18 to 49 years at high risk for severe RSV disease, expanding its previous indications for older adults [1].
  • The vaccine was previously limited to individuals aged 60 years and older or those aged 50 to 59 with increased risk factors [2].
  • The approval is based on clinical trial data demonstrating the vaccine's efficacy in preventing LRTI caused by RSV in the newly approved age group [3].
  • High-risk criteria for this age group include chronic lung disease, heart disease, or compromised immune systems [4].
  • The CDC recommends vaccination for this group to help mitigate the risk of severe RSV illness during peak RSV seasons [5].

What This Means for Your Practice

Primary care providers and specialists managing patients with chronic health conditions should now consider recommending Arexvy to high-risk adults aged 18 to 49 years. This change in the vaccination landscape allows for proactive prevention strategies against RSV in younger adults, who may not have previously qualified for vaccination. Clinicians should assess patients for underlying health issues that place them at higher risk for severe RSV disease and discuss the benefits of vaccination, especially as RSV season approaches. Additionally, monitoring for potential side effects and ensuring patients understand the importance of vaccination can enhance compliance. How will your practice integrate this new recommendation into routine care for high-risk adults?

Sources and Further Reading

[1] Centers for Disease Control and Prevention — Respiratory Syncytial Virus (RSV) Vaccine Safety. 2025. URL: https://www.cdc.gov/vaccine-safety/vaccines/rsv.html

[2] Centers for Disease Control and Prevention — Use of Respiratory Syncytial Virus Vaccines for Adults. 2024. URL: https://www.cdc.gov/mmwr/volumes/73/wr/mm7332e1.htm

[3] National Institutes of Health — Immune System. 2023. URL: https://www.nih.gov/about-nih/impact-nih-research/improving-health/immune-system

[4] Centers for Disease Control and Prevention — RSV Vaccine VIS. 2025. URL: https://www.cdc.gov/vaccines/hcp/current-vis/rsv.html

[5] Centers for Disease Control and Prevention — Respiratory Syncytial Virus (RSV). 2025. URL: https://www.cdc.gov/rsv/index.html